Back to search

Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B

NCT03905655

PHASE2INTERVENTIONAL
Romark Laboratories L.C.
51 participants
Started 2019-10-22 · Completed 2021-10-11
Status: Completed (as of 12-23-2025)

Conditions

Chronic Hepatitis B

Interventions

DRUG: Placebo Oral TabletDRUG: Nitazoxanide

Linked Papers (from SciSciNet-V2)

Total Papers0
Background
0
Result
0
Derived
0
Unknown
0
View on ClinicalTrials.gov

Brief Summary

This randomized controlled trial is designed to evaluate safety, effectiveness and pharmacokinetic-pharmacodynamic (PK/PD) relationships associated with three different Nitazoxanide (NTZ) treatment regimens added to Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide (TAF) or Entecavir (ETV) in treating Chronic Hepatitis B (CHB).

No papers linked to this trial in SciSciNet

Visit ClinicalTrials.gov for more information about this study